Stocks · News reference
Leerink Partners analyst Roanna Ruiz maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Outperform and raises the price target from $12 to $16.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Initiation of Phase 3 registrational study on track by year-end; topline results expected in late 2028; U.S. FDA approval and launch anticipated in 2030The Company expects XP-8121 peak net revenue potential of $1 to $3
Filed: 2026-09-09 AccNo: 0001867096-26-000077 Size: 3 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Barclays analyst Glen Santangelo maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Overweight and raises the price target from $9 to $12.